文献速递结核与非结核分枝杆菌艾滋病与性传播感染

南非高HIV流行区口服短程方案治疗耐利福平结核的项目化结局

Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa.
PubMed 文献 · Clin Infect Dis · 2025-01-01

该前瞻性队列研究在南非东开普省纳入248例新诊断耐利福平结核成人,其中69.8%为HIV阳性,评估含利奈唑胺的七药口服短程方案。治疗成功率为37.5%(93/248),18个月无结核生存率为63.3%,基线3+涂片、较高年龄和较低白蛋白与18个月不良结局相关,而HIV状态无关。

要点

  • 口服短程方案治疗成功率为37.5%(93/248),18个月无结核生存率为63.3%。
  • 90天痰培养转阴率为96.8%,中位转阴时间29天(95%CI 27-31)。
  • 基线3+涂片、较高年龄和较低白蛋白与18个月不良结局相关,HIV状态无关。

核心结论

  • 含利奈唑胺的七药口服短程方案在高负担结核规划环境中表现不佳,治疗成功率为37.5%(93/248)。

研究设计与样本

  • 前瞻性队列研究,纳入南非东开普省新诊断耐利福平结核成人248例,其中173例(69.8%)为HIV阳性。

主要发现

  • 90天痰培养转阴率为96.8%,中位转阴时间29天(95%CI 27-31)。
  • 治疗成功率为37.5%(93/248);未成功原因包括更换为个体化方案35.1%(87/248)、失访19.4%(48/348)和死亡8.1%(20/248)。
  • 18个月时157例(63.3%)达到无结核生存,累积死亡率为21.6%(95%CI 16.1-29.0)。
  • 基线3+涂片(aOR 3.38,95%CI 1.28-8.95)、较高年龄(aOR 1.05,95%CI 1.01-1.08)和较低白蛋白(aOR 0.94,95%CI 0.88-0.99)与18个月不良结局相关,HIV状态无关联。

临床怎么用

  • 在高HIV流行、高结核负担的项目化环境中,该口服短程方案的治疗成功率低于临床试验报告的水平。
  • 需要支持有效新方案实施的策略,以将临床试验结局转化为实践。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bedaquiline-based oral short-course regimens (SCR) for rifampicin-resistant tuberculosis (RR-TB) are highly effective in clinical trials but outcomes in programmatic settings may be more modest. We evaluated clinical and bacteriological outcomes with a seven-drug, linezolid-containing SCR in a high-burden programmatic setting. METHODS: This prospective cohort study enrolled adults with newly diagnosed RR-TB who were started on the oral SCR in the Eastern Cape Province, South Africa. The primary outcome was World Health Organization-defined end-of-treatment success. Secondary outcomes were TB-free survival (composite of alive, absence of a positive Mycobacterium tuberculosis culture, and treatment completed or in care) at 18 months and time to sputum culture conversion (SCC). RESULTS: In total, 248 participants were included, 173 (69.8%) of whom were human immunodeficiency virus (HIV) positive. Culture conversion by 90 days was 96.8% (median time to SCC: 29 days, 95% confidence interval [CI]: 27-31). Treatment success was 37.5% (93/248). Reasons for unsuccessful treatment included switching to individualised regimens (35.1%, 87/248), loss to follow-up (19.4%, 48/348), and death (8.1%, 20/248). At 18 months, 157 (63.3%) participants achieved TB-free survival, with a cumulative mortality of 21.6% (95% CI: 16.1-29.0). Baseline 3+ smear (adjusted odds ratio [aOR]: 3.38, 95% CI: 1.28-8.95), higher age (aOR: 1.05, 1.01-1.08), and lower albumin (aOR: 0.94, 0.88-0.99), but not HIV status, were associated with unfavourable outcome at 18 months. CONCLUSIONS: The oral SCR performed poorly in a high-burden TB programme. Strategies to support the implementation of effective new regimens for RR-TB are needed to translate outcomes from clinical trials into practice.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Stadler JAM, Kuhlin J, Molloy SF, et al. Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa. Clin Infect Dis. 2025. PMID: 40342012. doi:10.1093/cid/ciaf112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。